Gainers
- Synlogic (NASDAQ:SYBX) shares rose 12.1% to $0.67 during Wednesday's after-market session. The company's market cap stands at $47.2 million.
- Bone Biologics (NASDAQ:BBLG) shares rose 9.63% to $0.3. The market value of their outstanding shares is at $4.5 million.
- eFFECTOR Therapeutics (NASDAQ:EFTR) shares rose 6.28% to $0.44. The market value of their outstanding shares is at $18.4 million.
- MEI Pharma (NASDAQ:MEIP) stock increased by 5.82% to $0.36. The market value of their outstanding shares is at $47.9 million.
- Molecular Templates (NASDAQ:MTEM) shares rose 5.64% to $0.56. The market value of their outstanding shares is at $31.5 million.
- bioAffinity Technologies (NASDAQ:BIAF) stock rose 5.18% to $2.84. The company's market cap stands at $23.7 million.
Losers
- Aziyo Biologics (NASDAQ:AZYO) stock decreased by 18.9% to $5.6 during Wednesday's after-market session. The market value of their outstanding shares is at $77.1 million.
- Applied Therapeutics (NASDAQ:APLT) shares decreased by 14.29% to $0.96. The market value of their outstanding shares is at $46.1 million.
- Biophytis (NASDAQ:BPTS) stock decreased by 11.95% to $0.59. The company's market cap stands at $12.0 million.
- Biodesix (NASDAQ:BDSX) stock declined by 11.0% to $1.78. Trading volume for this security closed at 96.5K, accounting for 51.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $145.5 million.
- Akanda (NASDAQ:AKAN) stock declined by 8.45% to $0.21. Trading volume for this security closed at 238.6K, accounting for 34.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.0 million.
- Scopus BioPharma (NASDAQ:SCPS) stock fell 6.91% to $0.2. The company's market cap stands at $4.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
